AbbVie reports first-ever quarter, downplays Pfizer impact

Share this article:

AbbVie's first quarter as a standalone company ended in the black, with $4.3 billion in sales and $968 million in earnings. Sales of cornerstone product Humira were $2.4 billion for the quarter ended March 31, and the company saw Synagis sales reach $345 million, and AndroGel sales reach $240 million.

The company reiterated during Friday's earnings call that it remains committed to Humira. Although Europe's regulator refused Pfizer's Xeljanz for approval Thursday, AbbVie execs shrugged off the potential implications for its hold on the RA market. SVP John Leonard told analysts the RA market is a tough one to enter. CEO Richard Gonzalez noted that Humira has been holding its own in the RA market, and while it expects RA growth to continue to grow at a single-digit pace, Humira's major growth opportunities are in dermatology and gastroenterology, where is it seeing double-digit expansion. Gonzalez also noted emerging markets and biosimilars aren't a major company focus at this time because “roughly 80% of our revenues come from emerging markets,” which means AbbVie has not seen “any material impact from any biosimilar competition.”

AbbVie said its JAK-2 inhibitor research is progressing and is well into is Phase I development. The company expects the next generation of Hepatitis C treatments to begin to surface around 2015 and that its offerings will be easy to administer with fewer side effects. AbbVie announced earlier this week that its experimental five-pill HCV regimen wiped out the virus in at least 88% of treatment-naïve patients after eight weeks of treatment.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...